Merck Gets China Nod on HPV Shot for Men

Merck says its HPV vaccine for men was approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration.
Merck Gets China Nod on HPV Shot for Men Amid Sales Slump
China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the US drug giant after a rush among women to get the shot lost steam.
Merck's HPV Vaccine Gains Ground in China
U.S. drugmaker Merck & Co has received approval in China for its HPV vaccine's use in males, expanding its market reach despite earlier weak sales in the region. This move marks a potential growth opportunity as Gardasil has been key to Merck's market strategy alongside cancer treatment Keytruda.
Merck's HPV vaccine gets China approval for men amid declining sales
Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a much-needed boost in a key market where demand has been falling among women.
Merck’s Gardasil receives expanded approval for males in China
Merck (MRK) announced that the National Medical Products Administration of China approved Gardasil Vaccine for use in males 9-26 years of age
Merck's HPV Vaccine Gains Approval in China for Men
Merck & Co announced that its HPV vaccine has received approval from China's medical products administration for use in males aged 9-26 years. This marks a significant development in extending preventive healthcare to a broader demographic in China.
bovnews4h
What’s Fueling Merck & Co Inc (MRK) Stock’s -13.49% Loss Below Its 200-Day SMA?
Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $101.02 which represents a slight increase of $1.30 or 1.30% from the prior close of $99.72. The stock opened at $100.13 and touched a ...
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
Unpacking the Latest Options Trading Trends in Merck & Co
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
China's WuXi Biologics to sell Irish vaccine facility to Merck for $500 million
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Zacks.com on MSN1d
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) ended the recent trading session at $99.72, demonstrating a +0.59% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.55%.
Merck says HPV vaccine for men approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...